NeOnc Technologies Holdings, Inc. filed a Form 8-K on November 3, 2026, disclosing that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology on November 13, 2026.

Key Highlights

  • Two posters scheduled: Data from both the intranasal NEO100 and oral NEO212 programs will be presented on November 13, 2026, according to the filing.
  • Conference details: The Society for Neuro-Oncology 31st Annual Meeting and Education Day runs November 12 through November 15, 2026, in Philadelphia, Pennsylvania.
  • Press release date: The company issued its press release on November 2, 2026, which is furnished as Exhibit 99.1 to the filing.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company under applicable SEC rules.
  • Disclosure classification: The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Securities Exchange Act of 1934.

NeOnc Technologies to Present NEO100 and NEO212 Program Data at SNO Annual Meeting

According to the Form 8-K filed with the SEC on November 3, 2026, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) announced via a press release dated November 2, 2026, that scientific data from two of its drug programs will be featured at a major neuro-oncology conference. The company disclosed that data from its intranasal NEO100 program and its oral NEO212 program are each slated for poster presentations at the event.

The presentations are scheduled for November 13, 2026, during the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology, which the filing states will be held November 12 through November 15, 2026, in Philadelphia, Pennsylvania. The company furnished a copy of the press release as Exhibit 99.1 to the current report.

The filing was signed by Amir Heshmatpour, identified as Chief Executive Officer, President and Executive Chairman of NeOnc Technologies Holdings, Inc., and dated November 3, 2026. The company is incorporated in Delaware and maintains principal executive offices at 23975 Park Sorrento, Suite 205, Calabasas, CA 91302. As noted in the filing, the Item 7.01 disclosure and accompanying exhibit are furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

What Was Disclosed

NeOnc Technologies Holdings, Inc. disclosed via an 8-K that data from its NEO100 and NEO212 programs will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology 31st Annual Meeting in Philadelphia, Pennsylvania.